Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: Value of cardiac and pulmonary iodine-123 MIBG uptake

European Journal of Nuclear Medicine

Volumn 27, Issue 5, 2000, Pages 595-600

  Reinhardt, Michael J ^a   Jüngling, Freimut D ^a   Krause, Thomas M ^a   Braune, Stefan ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Metaiodobenzylguanidine; Parkinson's disease Multiple system atrophy; Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DYSAUTONOMIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; SCINTIGRAPHY; SHY DRAGER SYNDROME; TREATMENT INDICATION;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; AUTONOMIC NERVOUS SYSTEM DISEASES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEART; HUMANS; IODINE RADIOISOTOPES; LUNG; MALE; MEDIASTINAL DISEASES; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; MYOCARDIUM; PARKINSON DISEASE; RADIOPHARMACEUTICALS;

EID: 0034102618     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050548     Document Type: Article

References (19)

1. 1. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996; 46: 1470.
2. 2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
3. 3. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. Brain 1994; 117: 835-845.
4. 4. Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: Bannister R, Mathias CJ, eds. Autonomic failure, 3rd edn. New York: Oxford University Press; 1992: 593-621.
5. 5. Murashima S, Takeda K, Matsumura K, et al. Increased lung uptake of iodine-123-MIBG in diabetics with sympathetic nervous dysfunction. J Nucl Med 1998; 39: 334-338.
6. 6. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992; 32: 125-127.
7. 7. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement disorders III. London: Butterworth-Heinemann; 1994: 262-281.
8. 8. Braune S, Auer A, Schulte-Mönting J, Schwerbrock S, Lücking CH. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal subjects. Clin Autonom Res 1996; 6: 3-15.
9. 9. Nakano M, Shimabukuro K, Yoshimura H, et al. Iodine-131-metaiodobenzylguanidine intra-and extra-vesicular accumulation in the rat heart. J Nucl Med 1986; 27: 84-89.
10. 10. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabeled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992; 13: 513-521.
11. 11. Pothos E, Desmond M, Sulzer D. L-3,4-Dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J Neurochem 1996; 66: 629-636.
12. 12. Probst-Cousin S. Characterization of multiple system atrophy. First international congress in London, March 22 and 23, 1997. Dtsch Ärztebl 1997; 94: 1382-1383.
13. 13. Sisson JC, Wieland DM, Sherman P, Manger TJ, Tobes MC, Jaques S. Metaiodo-bezylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987; 27: 1620-1624.
14. 123I-meta-iodobenzylguanidine in Parkinson's disease. Nucl Med Commun 1998; 19: 137-142.
15. 15. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodo-benzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60-67.
16. 16. Cohen J, Low P, Fealey R, Sheps S, Jiang NS. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 1987; 22: 692-699.
17. 17. Ando Y, Obayashi K, Tanaka Y, et al. Radiolabelled metaiodobenzylguanidine in assessment of autonomic dysfunction. Lancet 1994; 343: 984-985.
18. 18. Rajput AH, Rozdilsky B. Dysautonomia in parkinsonism: a clinopathological study. J Neurol Neurosurg Psychiatry 1976; 39: 1092-1100.
19. 19. Orskov L, Jakobsen J, Dupont E, de Fine O, Christensen NJ. Autonomic function in Parkinsonian patients relates to duration of disease. Neurology 1987; 37: 1173-1178.